Biocompatibility evidence: assess gaps before buying a test panel
The acquired FDA guidance places biological evaluation within risk management. Existing material, processing and clinical evidence can inform the assessment, but relevance to the final finished device must be demonstrated. Contact category alone does not prescribe a complete test panel: compare the proposed device, the evidence already available and the remaining risks.
Evidence retrieved 2026-10-06. Source versions and topic-specific limits are listed below.
Sourced criteria · US
What changes the service scope?
Decision or task
What the source describes
What to prepare
What device is actually being evaluated?
The risk assessment considers the final finished device and manufacturing/processing effects, rather than treating a raw-material name as complete evidence. [1]
Inventory materials, processing, sterilization, contact and the proposed use; identify changes from any previously evaluated design.
Which existing evidence is relevant?
The guidance discusses supplier/master-file information, chemical/surface analysis and published experience, while asking how an evaluated device compares to the proposed device. [2]
Build an evidence applicability matrix; record differences, missing access and limits instead of assuming the same polymer establishes equivalence.
How are knowledge gaps resolved?
FDA recommends considering available relevant information in the risk assessment to reduce unnecessary testing, including animal testing. [1][3]
Ask the specialist to connect each proposed investigation to an unresolved risk and to explain why existing evidence is insufficient.
Does every endpoint mean a new test?
The acquired guidance distinguishes endpoint evaluation from an assumption that every endpoint warrants testing. [4]
Request a biological-evaluation rationale with justified methods, relevant exposure and endpoint coverage; do not purchase an unexplained fixed panel.
Guidance is not a universal mandatory test list. Device-specific requirements, standard recognition/editions, material identity, exposure and complete study evidence remain to be reviewed. This page cannot certify biological safety.
A scoped evidence and handoff plan
Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.
What device is actually being evaluated?
Inventory materials, processing, sterilization, contact and the proposed use; identify changes from any previously evaluated design.
Useful evidence: Final-device materials/process map, contact description and change history.
Which existing evidence is relevant?
Build an evidence applicability matrix; record differences, missing access and limits instead of assuming the same polymer establishes equivalence.
Useful evidence: Supplier evidence/access permissions, referenced reports and a tested-versus-proposed comparison.
How are knowledge gaps resolved?
Ask the specialist to connect each proposed investigation to an unresolved risk and to explain why existing evidence is insufficient.
Useful evidence: Risk/evidence/gap matrix and the rationale for each proposed study.
Does every endpoint mean a new test?
Request a biological-evaluation rationale with justified methods, relevant exposure and endpoint coverage; do not purchase an unexplained fixed panel.
Useful evidence: Biological-evaluation plan, exposure/contact facts and study or alternative-evidence rationale.
Work packages and dependencies
Conditional: Biological-evaluation plan and justified evidence gaps — For this work package, agree the supported criteria, evidence access, covered entities/products and unresolved facts in the table above. Additional services require their own justified scope.
Optional: Processing/sterilization change evidence where relevant — For this work package, agree the supported criteria, evidence access, covered entities/products and unresolved facts in the table above. Additional services require their own justified scope.
Questions for providers
Which exact actor, product or processing facts support the quoted scope, and what is still unresolved?
How will the listed records reach the responsible people, and who owns each change or authority request?
Which tasks and entities are excluded from the agreement, and which additional services need a separate assessment?
Sources and data dates
Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.
